GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing
Greater Cannabis Company (OTC: GCAN) has announced its exploration of strategic alternatives in Artificial Intelligence and Quantum Computing sectors while maintaining its existing biopharmaceutical business. The company is evaluating various options including potential sale, merger, or strategic business combinations in response to interest from companies developing cutting-edge technologies.
CEO Aitan Zacharin indicated that multiple companies in these emerging technology sectors have approached GCAN expressing interest in potential mergers. The company emphasizes that while it's exploring these opportunities to maximize shareholder value, there's no guarantee that any transaction will be completed or that favorable terms will be achieved. No specific timeline has been set for completing this evaluation process.
Greater Cannabis Company (OTC: GCAN) ha annunciato l'esplorazione di alternative strategiche nei settori Intelligenza Artificiale e Calcolo Quantistico, mantenendo comunque il suo attuale business biopharmaceutico. L'azienda sta valutando diverse opzioni, tra cui potenziali cessioni, fusioni o combinazioni aziendali strategiche, in risposta all'interesse da parte di imprese che sviluppano tecnologie all'avanguardia.
Il CEO Aitan Zacharin ha indicato che diverse aziende in questi settori tecnologici emergenti si sono rivolte a GCAN esprimendo interesse per possibili fusioni. L'azienda sottolinea che, mentre esplora queste opportunità per massimizzare il valore per gli azionisti, non c'è garanzia che venga completata alcuna transazione o che si raggiungano condizioni favorevoli. Non è stato fissato un cronoprogramma specifico per completare questo processo di valutazione.
Greater Cannabis Company (OTC: GCAN) ha anunciado su exploración de alternativas estratégicas en los sectores de Inteligencia Artificial y Computación Cuántica, mientras mantiene su negocio biofarmacéutico existente. La compañía está evaluando varias opciones, incluyendo una venta, fusión o combinaciones empresariales estratégicas, en respuesta al interés de empresas que desarrollan tecnologías de vanguardia.
El CEO Aitan Zacharin indicó que múltiples empresas en estos sectores de tecnología emergente se han acercado a GCAN expresando interés en posibles fusiones. La compañía enfatiza que, si bien está explorando estas oportunidades para maximizar el valor para los accionistas, no hay garantía de que se complete ninguna transacción ni de que se logren condiciones favorables. No se ha establecido un cronograma específico para completar este proceso de evaluación.
Greater Cannabis Company (OTC: GCAN)는 기존의 생물의약품 사업을 유지하면서 인공지능 및 양자 컴퓨팅 분야에서 전략적 대안을 모색한다고 발표했습니다. 이 회사는 최첨단 기술을 개발하는 기업들의 관심에 대응하여 매각, 합병 또는 전략적 사업 결합을 포함한 여러 옵션을 평가하고 있습니다.
CEO Aitan Zacharin은 이러한 신흥 기술 분야에서 여러 기업들이 GCAN에 접근하여 잠재적인 합병에 대한 관심을 표명했다고 밝혔습니다. 이 회사는 주주 가치를 극대화하기 위해 이러한 기회를 탐색하고 있지만, 어떠한 거래가 완료되거나 유리한 조건이 달성될 것이라는 보장은 없다고 강조합니다. 이 평가 프로세스를 완료하기 위한 특정 일정은 설정되지 않았습니다.
Greater Cannabis Company (OTC: GCAN) a annoncé son exploration d'alternatives stratégiques dans les secteurs de l'Intelligence Artificielle et de l'Informatique Quantique, tout en maintenant son activité biopharmaceutique existante. L'entreprise évalue diverses options, y compris une vente, une fusion ou des combinaisons d'affaires stratégiques, en réponse à l'intérêt d'entreprises développant des technologies de pointe.
Le PDG Aitan Zacharin a indiqué que plusieurs entreprises dans ces secteurs technologiques émergents ont approché GCAN en exprimant un intérêt pour des fusions potentielles. L'entreprise souligne que bien qu'elle explore ces opportunités pour maximiser la valeur pour les actionnaires, il n'y a aucune garantie qu'une transaction sera finalisée ou que des conditions favorables seront atteintes. Aucun calendrier spécifique n'a été fixé pour achever ce processus d'évaluation.
Greater Cannabis Company (OTC: GCAN) hat die Erkundung strategischer Alternativen in den Bereichen Künstliche Intelligenz und Quantencomputing angekündigt, während das bestehende biopharmazeutische Geschäft beibehalten wird. Das Unternehmen bewertet verschiedene Optionen, einschließlich potenzieller Verkäufe, Fusionen oder strategischer Unternehmenszusammenschlüsse, als Reaktion auf das Interesse von Unternehmen, die Spitzentechnologien entwickeln.
CEO Aitan Zacharin gab an, dass mehrere Unternehmen in diesen aufstrebenden Technologiesektoren GCAN angesprochen haben und Interesse an möglichen Fusionen geäußert haben. Das Unternehmen betont, dass es diese Chancen erkundet, um den Wert für die Aktionäre zu maximieren, aber es gibt keine Garantie, dass eine Transaktion abgeschlossen oder günstige Bedingungen erzielt werden. Es wurde kein spezifischer Zeitrahmen für den Abschluss dieses Bewertungsprozesses festgelegt.
- Multiple companies have expressed interest in potential merger opportunities
- Company maintains existing biopharmaceutical business while exploring new growth avenues
- Expansion into high-growth AI and quantum computing sectors
- No guarantee of successful transaction completion
- No defined timeline for strategic evaluation process
- Uncertainty regarding terms and conditions of potential deals
- Company today announced a major strategic step forward as it explores new growth avenues
- Artificial Intelligence (AI) and Quantum Computing industries represent multi-trillion dollar market opportunities1,2
- Company is committed to maximize shareholder value through evaluation of strategic options
BALTIMORE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics would like to update its shareholders that has initiated a process to explore strategic alternatives to maximize shareholder value. The Company will continue to pursue its existing biopharma lines of business while evaluating a range of strategic options to maximize value for its shareholders. The business fields of quantum computing and AI are seen as the next frontier in emerging technologies, and have quickly developed into multi-billion dollar industries.
Aitan Zacharin, Chief Executive Officer, had this to say, “There have been a number of companies focused on developing these cutting edge technologies who have approached GCAN expressing interest in a potential merger, and as part of our fiduciary obligation to our shareholders we will explore these options. We look forward to updating our shareholders with continued developments.”
As part of the evaluation process GCAN will explore potential strategic alternatives that may include, but are not limited to a sale, merger, strategic business combination or other transaction. The Company cannot assure that its exploration will result in a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. The Company has not set a timetable for completion of the evaluation process. GCAN will make further announcements in accordance with its ongoing disclosure obligations and pursuant to applicable laws and regulations.
ENDS
For GCANRx Investor Relations inquiries visit www.gcanrx.com, or contact info@gcanrx.com. To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.
1 https://www.mckinsey.com/featured-insights/the-rise-of-quantum-computing
2 https://www.bloomberg.com/company/press/generative-ai-to-become-a-1-3-trillion-market-by-2032-research-finds/
About Greater Cannabis Company: The Greater Cannabis Company (OTC: GCAN), (“GCANRx” or the “Company”) is a publicly traded clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop innovative cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. GCANRx’s mission is to bring its products to the global market for the benefit of patients seeking better solutions for their unmet medical needs.
Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com
FAQ
What strategic alternatives is GCAN exploring in 2025?
How will GCAN's strategic exploration affect current shareholders?
What industries is GCAN targeting for potential mergers in 2025?
Has GCAN set a timeline for completing its strategic evaluation?
What companies have approached GCAN for potential mergers?
